| Literature DB >> 29019147 |
H Kearney1, A M Cahalane2, R P Killeen2, C McGuigan3.
Abstract
The diagnosis of multiple sclerosis (MS) is based on a history consistent with demyelination of the central nervous system and corresponding physical signs on examination. However, this diagnosis is supported radiologically using magnetic resonance imaging (MRI). At present, MRI serves as the most reliable and widely available biomarker for the practising clinician to measure disease activity and treatment response in MS. As MRI remains central to both the diagnosis and management of MS, this paper provides proposed guidelines for its use in routine clinical practice.Entities:
Keywords: Disease-modifying drugs; MRI; MS; PML
Mesh:
Year: 2017 PMID: 29019147 DOI: 10.1007/s11845-017-1691-z
Source DB: PubMed Journal: Ir J Med Sci ISSN: 0021-1265 Impact factor: 1.568